CRP and deep vein thrombosis: In the CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), a monoclonal antibody targeting IL-1β canakinumab was shown to reduce the level of the inflammatory marker C-reactive protein (CRP) and to reduce the cardiovascular risk, without influencing blood lipid profile [15].